Clinical observation on the treatment of Middle-Aged Chronic Migraine with Qiye Shenan tablet and Sumatriptan
10.3969/j.issn.1005-1678.2017.05.067
- VernacularTitle:七叶神安片联合舒马普坦治疗中老年慢性偏头痛的临床效果观察
- Author:
Chenjuan TAO
;
Weiwei YAN
;
Qiuying SONG
;
Xiaochuan WANG
- Keywords:
Qiye Shenan tablet;
sumatriptan;
middle-aged;
chronic migraine
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):206-208
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of Qiye Shenan tablet combined with sumatriptan in the treatment of middle-aged and elderly patients with chronic migraine.MethodsA total of 124 elderly patients with chronic migraine treated in our hospital from July 2015 to December 2015 were selected.The patients were divided into two groups according to the principle of randomization, with 62 cases in each group.The control group was treated with sumatriptan, The observation group was treated with Qiye Shenan tablet on this basis.The curative effect of the two groups, the relevant indicators and adverse reactions were analyzed.ResultsThe effective rate was 95.16% in the observation group, which was higher than that in the control group (80.65%, P<0.05).After treatment, the VAS score and the main symptom scores of the observation group were (1.86±0.42,3.48±0.59), respectively, which were lower than those in the control group (3.19±0.50,5.06±0.64) (P<0.05).The level of nitric oxide (NO) in the observation group was (33.04±3.86)μmol/L, which was lower than that in the control group (40.92±4.28)μmol/L(P<0.05).The adverse reaction rate was 11.29% in the observation group, which was lower than that in the control group (17.74%), but there was no significant difference between the two groups.ConclusionQiye Shenan tablet can improve the therapeutic effect of chronic migraine in the elderly, reduce the pain of the patients and improve the related symptoms, and the safety of medication.
